Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-400-7 | CAS number: 58-86-6
oral: Japan MHLW Guideline; LD50 > 2200 mg/kg bw (male rat) ; LD50 > 2500 mg/kg (female rat); reliability = 2
The two year carcinogenicity of the test substance was examined in groups of 50 male and 50 female F344 rats at dietary doses of 0% (control), 2.5% and 5%. Growth suppression and soft faeces were observed in male and female rats of the 5% group. However, no significant differences from the controls were noted with regard to clinical signs, mortality and haematological findings. None of the treated groups showed significant increase in the incidence of any specific tumour over the control group level. In conclusion, the present results demonstrate that the test substance dose not exert any carcinogenic potential in male and female F344 rats fed for two years. The LD50 was calculated from the 104-week study to be >2200 mg/kg in males and >2500 mg/kg in female rats.
The test substance has low oral toxicity in the rat. The oral LD50 was > 2200 mg/kg in male rats and >2500 mg/kg in female rats.
Based on the acute male rat oral LD50 of > 2200 mg/kg and acute female rat oral LD50 of >2500 mg/kg, no classification is required for acute oral toxicity according to EU Directive 67/548/EEC and EU Classification and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
Physicochemical and toxicological properties of D-xylose do not suggest a potential for a significant rate of absorption. Further, xylose has been extensively reviewed and approved for human consumption. In addition, within all the years of xylose being used in foodstuffs and being supplied to numerous sectors, whereby it is handled, there has never been a report regarding toxicological concerns upon dermal exposure. The toxicity of xylose has been studied extensively, including an oral two-year study, and no systemic toxicity has been demonstrated. Therefore, no classification is required for acute dermal toxicity according to EU Directive 67/548/EEC and EU Classification and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
Data lacking due to waiving arguments, so substance cannot be classified for acute inhalation toxicity according to EU Directive 67/548/EEC and EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again